TRANCORE TABLET

A Common Acquired Disorder of HYPERPIGMENTATION

• A novel treatment for melasma with multimodal mechanism of action
• Provides a comprehensive treatment of melasma
• Inhibits the plasminogen/plasmin pathway
• Inhibits the interactions between melanocytes & keratinocytes
• Targets both dark spots and mask-like discolorations
• Targets the inflammatory pathways that lead to increased pigmentation
• Allows skin’s surface layers to regain their natural, even-toned color
• Takes 8-12 weeks of daily use for significant results
• Also serves a safe therapeutic option with least side effects
• Considered in cases that are unresponsive to topical hydroquinone and combination topical therapy

Tranexamic acid Exhibits Hypopigmentary Effect by Two Mechanism of Action

• Inhibits plasmin activity & thus reduces melanin synthesis
• Tranexamic acid structure resembles tyrosine and hence it may competitively inhibit tyrosinase